徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

LH 徕博科

盘前交易 03-10 04:00:08 EDT

273.61

+3.94

+1.46%

最高274.35	最低264.24	成交量56.31万
今开268.38	昨收269.67	日振幅3.75%
总市值225.45亿	流通市值225.45亿	总股本8,240万
成交额1.53亿	换手率0.68%	流通股本8,240万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"LH","market":"US","secType":"STK","nameCN":"徕博科","latestPrice":273.61,"timestamp":1773086400000,"preClose":269.67,"halted":0,"volume":563147,"delay":0,"changeRate":0.014610449809025837,"floatShares":82400000,"shares":82400000,"eps":10.46,"marketStatus":"盘前交易","change":3.94,"latestTime":"03-10 04:00:08 EDT","open":268.38,"high":274.35,"low":264.24,"amount":152510648.34537998,"amplitude":0.03749,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":10.46,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773149400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":672379200000,"exchange":"NYSE","adjPreClose":273.61,"dividendRate":0.010526,"postHourTrading":{"tag":"盘后","latestPrice":273.61,"preClose":273.61,"latestTime":"16:46 EDT","volume":12749,"amount":3488253.89,"timestamp":1773089162566,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.238312,"impliedVol":0.2805,"impliedVolPercentile":0.708},"requestUrl":"/m/hq/s/LH","defaultTab":"news","newsList":[{"id":"1116901456","title":"徕博科深化与PathAI合作 将在全美部署FDA认证数字病理平台","url":"https://stock-news.laohu8.com/highlight/detail?id=1116901456","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116901456?lang=zh_cn&edition=full","pubTime":"2026-02-23 20:03","pubTimestamp":1771848188,"startTime":"0","endTime":"0","summary":"徕博科宣布扩大与人工智能诊断公司PathAI的战略合作，将在美国境内全面推广经美国食品药品监督管理局（FDA）批准的数字病理学平台。此次升级合作将整合双方在诊断技术与算法开发领域的优势资源，通过数字化切片扫描和AI辅助分析系统，提升病理诊断的标准化程度与判读效率。该平台能实现组织样本的云端存储、多重分析及远程会诊功能，预计将优化医疗机构的运营流程，为临床医生提供更精准的定量化诊断依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH","LU0048573561.USD","LU0742534661.SGD","BK4588","BK4550","BK4196","LU0251131958.USD","LU1059921491.USD","LU0006061336.USD","LU2237438978.USD","BK4585","LU0251142724.SGD"],"gpt_icon":0},{"id":"1128514647","title":"财报前瞻｜徕博科本季度营收预计增7.55%，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1128514647","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128514647?lang=zh_cn&edition=full","pubTime":"2026-02-10 10:14","pubTimestamp":1770689695,"startTime":"0","endTime":"0","summary":"徕博科将在2026年02月17日发布最新季度财报，市场关注营收、毛利率与EPS的变化及临床实验室诊断业务延续增长态势。市场一致预期显示，本季度徕博科总营收预计为35.58亿美元，同比增长7.55%；调整后每股收益预计为3.94美元，同比增长16.38%；息税前利润预计为4.87亿美元，同比增长12.56%。多家机构强调本季度EPS与EBIT的增长弹性，认为营收增长7.55%与EPS增长16.38%的预期具备实现基础，若费用率改善进一步兑现，EPS有望高于一致预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜徕博科本季度营收预计增7.55%，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"gpt_icon":0},{"id":"1143070189","title":"徕博科增加1.25亿美元弹性贷款额度 可在2026年5月29日前随时将总额提升至8.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1143070189","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143070189?lang=zh_cn&edition=full","pubTime":"2026-01-30 05:43","pubTimestamp":1769722985,"startTime":"0","endTime":"0","summary":"根据最新提交给美国证券交易委员会的文件显示，徕博科（Labcorp）已新增一项1.25亿美元的弹性贷款安排。该协议允许公司在2026年5月29日或之前的任何时间点，将总信贷额度最高提升至8.25亿美元。\n这项弹性机制为徕博科提供了显著的财务灵活性，使其能够根据市场环境变化或战略需求快速调整资金规模。通过设置明确的时间窗口，公司既可规避长期资金沉淀成本，又能确保在关键时刻获得充足流动性支持。\n此次额度扩充延续了徕博科一贯的稳健财务管理策略。在医疗检测行业加速整合的背景下，增强的信贷能力将为潜在并购活动或技术升级提供有力保障，进一步巩固其行业领导地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","LU0251131958.USD","LU0006061336.USD","BK4585","LU1059921491.USD","BK4588","LH","LU0742534661.SGD","LU2237438978.USD","LU0048573561.USD","LU0251142724.SGD","BK4196"],"gpt_icon":0},{"id":"1146959120","title":"Namsa宣布战略性收购徕博科早期开发医疗器械测试业务精选资产","url":"https://stock-news.laohu8.com/highlight/detail?id=1146959120","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146959120?lang=zh_cn&edition=full","pubTime":"2026-01-08 21:30","pubTimestamp":1767879034,"startTime":"0","endTime":"0","summary":"Namsa公司近日披露，已成功完成对徕博科（Labcorp Holdings Inc）旗下早期开发医疗器械测试业务部分精选资产的战略性收购。此次交易将强化Namsa在医疗器械测试领域的服务能力，拓展其早期开发阶段的业务布局。通过整合优质资源，Namsa旨在提升综合解决方案水平，为全球医疗器械客户提供更高效、专业的支持服务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237438978.USD","BK4196","LU0006061336.USD","BK4550","BK4588","LU0048573561.USD","BK4585","LU1059921491.USD","LU0251142724.SGD","LU0742534661.SGD","LH","LU0251131958.USD"],"gpt_icon":0},{"id":"1159148699","title":"Labcorp 2025财年Q3业绩会总结及问答精华：诊断业务强劲增长，AI技术助力未来","url":"https://stock-news.laohu8.com/highlight/detail?id=1159148699","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159148699?lang=zh_cn&edition=full","pubTime":"2025-10-28 21:51","pubTimestamp":1761659513,"startTime":"0","endTime":"0","summary":"  本季度，Labcorp实现了9%的收入增长和19%的调整后每股收益增长，主要得益于诊断和中央实验室业务的强劲表现。自由现金流指导范围上调2500万美元至11.65亿-12.85亿美元。回答：本季度诊断收入同比增长8.5%，其中有机增长6%。  Labcorp在2025财年Q3表现出色，诊断和中央实验室业务的强劲增长推动了整体业绩的提升。AI技术和新诊断测试的推出为未来增长奠定了基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"gpt_icon":0},{"id":"1113622068","title":"异动解读 | 徕博科盘中大跌5.68%，下调2025年早期药物开发业务增长预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1113622068","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113622068?lang=zh_cn&edition=full","pubTime":"2025-10-28 21:33","pubTimestamp":1761658415,"startTime":"0","endTime":"0","summary":"周二盘中，徕博科（LH）股价大幅下跌5.68%，引发市场关注。这一显著跌幅似乎与公司最新发布的业务展望直接相关。\n\n根据公司高管在最新电话会议上的表态，徕博科预计2025年早期药物开发业务将实现低个位数增长，这一预期较此前的中个位数增长有所下调。这一消息无疑打击了投资者信心，导致股价应声下跌。\n\n作为一家领先的生命科学公司，徕博科的早期药物开发业务是其核心收入来源之一。增长预期的下调可能暗示该业务segment面临的挑战增加，或整体市场环境趋于保守。分析人士指出，这一调整可能会影响投资者对公司未来盈利能力的判断，进而导致股价承压。投资者将密切关注公司后续的业务发展和管理层的应对策略。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["LH"],"gpt_icon":0},{"id":"1193529848","title":"徕博科高管预计2025年早期药物开发业务将低个位数增长，早前预期为中个位数 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1193529848","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193529848?lang=zh_cn&edition=full","pubTime":"2025-10-28 21:25","pubTimestamp":1761657902,"startTime":"0","endTime":"0","summary":"徕博科高管表示，预计2025年早期药物开发业务将实现低个位数增长，而早前的预期为中个位数增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1059921491.USD","BK4550","LU0251142724.SGD","BK4196","LU0742534661.SGD","BK4585","LH","LU0006061336.USD","LU0048573561.USD","LU0251131958.USD","BK4588"],"gpt_icon":0},{"id":"1157057004","title":"徕博科推出首个经FDA认证的血液测试以排除初级医疗环境中的阿尔茨海默病相关淀粉样病理","url":"https://stock-news.laohu8.com/highlight/detail?id=1157057004","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157057004?lang=zh_cn&edition=full","pubTime":"2025-10-23 19:03","pubTimestamp":1761217388,"startTime":"0","endTime":"0","summary":"徕博科推出首个经FDA认证的血液测试以排除初级医疗环境中的阿尔茨海默病相关淀粉样病理","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251131958.USD","BK4588","LU0048573561.USD","LU1059921491.USD","BK4196","BK4550","LU0006061336.USD","LH","LU0251142724.SGD","LU0742534661.SGD","BK4585"],"gpt_icon":0},{"id":"2510472920","title":"徕博科2024财年实现净利润7.46亿美元，同比增加96.83%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510472920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510472920?lang=zh_cn&edition=full","pubTime":"2025-02-10 00:00","pubTimestamp":1739116854,"startTime":"0","endTime":"0","summary":"2月10日，徕博科公布财报，公告显示公司2024财年净利润为7.46亿美元，同比增加96.83%；其中营业收入为130.09亿美元，同比增加6.96%，每股基本收益为8.89美元。从资产负债表来看，徕博科总负债103.13亿美元，其中短期债务11.85亿美元，资产负债比为1.79，流动比率为1.45。机构评级：截至2025年2月10日，当前有16家机构对徕博科目标价做出预测，其中目标均价为271.81美元，其中最低目标价为240.00美元，最高目标价为293.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000129abc86720&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210000129abc86720&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LH"],"gpt_icon":0},{"id":"2509777981","title":"巴克莱：维持Labcorp Holdings(LH.US)评级，由持股观望调整至持股观望评级, 目标价由271.00美元调整至260.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509777981","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509777981?lang=zh_cn&edition=full","pubTime":"2025-02-08 06:27","pubTimestamp":1738967224,"startTime":"0","endTime":"0","summary":"巴克莱：维持Labcorp Holdings(LH.US)评级，由持股观望调整至持股观望评级, 目标价由271.00美元调整至260.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/08062748031987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LH"],"gpt_icon":0},{"id":"2509773590","title":"杰富瑞投资银行：维持Labcorp Holdings(LH.US)评级，由买入调整至买入评级, 目标价由275.00美元调整至290.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509773590","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509773590?lang=zh_cn&edition=full","pubTime":"2025-02-07 07:26","pubTimestamp":1738884368,"startTime":"0","endTime":"0","summary":"杰富瑞投资银行：维持Labcorp Holdings(LH.US)评级，由买入调整至买入评级, 目标价由275.00美元调整至290.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/07072648003359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LH"],"gpt_icon":0},{"id":"1191052054","title":"Labcorp第四季度财报：收入和每股收益超预期，预计2025年将实现强劲增长，分析师重申“表现优异”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1191052054","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191052054?lang=zh_cn&edition=full","pubTime":"2025-02-07 02:24","pubTimestamp":1738866295,"startTime":"0","endTime":"0","summary":"周四，Laboratory Corp报告其2024年第四季度调整后的每股收益为3.45美元，高于去年同期的3.30美元，超出市场预期的3.39美元。销售额同比增长9.8%，达到33.3亿美元，几乎与市场预期的33.1亿美元一致。调整后的季度运营收入为423.2百万美元，占收入的12.7%，而上一年同期为394.9百万美元，占收入的13%。这使得该股票在2025年具有稳定的指导性，并有可能在公司动能持续时获得收益。William Blair重申“表现优异”评级。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"gpt_icon":0},{"id":"1174528505","title":"实验室公司2024年第四季度调整后每股收益为3.45美元，超过预期的3.39美元，销售额为33.3亿美元，超过预期的33.1亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1174528505","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174528505?lang=zh_cn&edition=full","pubTime":"2025-02-06 19:54","pubTimestamp":1738842871,"startTime":"0","endTime":"0","summary":"相较于去年同期每股收益3.30美元，这是一个4.55%的增长。公司报告季度销售额为33.3亿美元，超过分析师普遍预期的33.1亿美元，超出0.63%。以上内容来自Benzinga Earnings专栏，原文如下：Laboratory Corp  reported quarterly earnings of $3.45 per share which beat the analyst consensus estimate of $3.39 by 1.77 percent. This is a 4.55 percent increase over earnings of $3.30 per share from the same period last year.  The company reported quarterly sales of $3.33 billion which beat the analyst consensus estimate of $3.31 billion by 0.63 percent.  This is a 9.76 percent increase o","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"gpt_icon":0},{"id":"1149955265","title":"Labcorp预计2025年销售额为138.8亿至140.5亿美元，对比市场预期的137.9亿美元，调整后每股收益为15.60至16.40美元，对比市场预期的16.02美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149955265","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149955265?lang=zh_cn&edition=full","pubTime":"2025-02-06 19:54","pubTimestamp":1738842859,"startTime":"0","endTime":"0","summary":"2025年指引假设外汇汇率截至2024年12月31日的全年有效。企业层面的指引包括当前预期的资本配置影响，包括收购、股票回购和股息。2024年Labcorp企业的收入为130.1亿美元，诊断实验室收入为101.4亿美元，生物制药实验室服务收入为29.2亿美元。调整后每股收益在2024年为14.57美元，2025年指引为15.60至16.40美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Labcorp预计2025年销售额为138.8亿至140.5亿美元，对比市场预期的137.9亿美元，调整后每股收益为15.60至16.40美元，对比市场预期的16.02美元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LH"],"gpt_icon":0},{"id":"2508218061","title":"巴克莱：维持Labcorp Holdings(LH.US)评级，由持股观望调整至持股观望评级, 目标价由249.00美元调整至271.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508218061","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508218061?lang=zh_cn&edition=full","pubTime":"2025-02-04 02:19","pubTimestamp":1738606781,"startTime":"0","endTime":"0","summary":"巴克莱：维持Labcorp Holdings(LH.US)评级，由持股观望调整至持股观望评级, 目标价由249.00美元调整至271.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/04021947942460.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LH"],"gpt_icon":0},{"id":"2507244696","title":"徕博科盘中异动 大幅上涨5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2507244696","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507244696?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:59","pubTimestamp":1738249143,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时59分，徕博科股票出现波动，股价大幅上涨5.02%。截至发稿，该股报258.59美元/股，成交量7.1283万股，换手率0.09%，振幅4.98%。徕博科股票所在的生命科学行业中，整体涨幅为3.94%。徕博科公司简介：徕博科控股有限公司是美国最大的两家独立临床实验室之一，拥有大约20%的独立实验室市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130225904a23459db&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130225904a23459db&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4196","LH","BK4550","BK4585","BK4588","LU0006061336.USD"],"gpt_icon":0},{"id":"2501874387","title":"Evercore ISI Group：上调Labcorp Holdings评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2501874387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501874387?lang=zh_cn&edition=full","pubTime":"2025-01-08 00:27","pubTimestamp":1736267242,"startTime":"0","endTime":"0","summary":"evercore ISI Group：上调Labcorp Holdings(LH.US)评级，由大市同步调整至优于大市评级,目标价由260.00美元调整至265.00美元。徕博科(LH.US)公司简介：徕博科控股公司从事医疗检测服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108003541a21902d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108003541a21902d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LH","EVR"],"gpt_icon":0},{"id":"2501678111","title":"Evercore ISI Group：上调Labcorp Holdings(LH.US)评级，由大市同步调整至优于大市评级, 目标价由260.00美元调整至265.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2501678111","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2501678111?lang=zh_cn&edition=full","pubTime":"2025-01-08 00:14","pubTimestamp":1736266451,"startTime":"0","endTime":"0","summary":"Evercore ISI Group：上调Labcorp Holdings(LH.US)评级，由大市同步调整至优于大市评级, 目标价由260.00美元调整至265.00美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/08001447233894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LH","EVR"],"gpt_icon":0},{"id":"2480670058","title":"徕博科2024财年第三财季实现净利润1.69亿美元，同比减少7.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2480670058","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480670058?lang=zh_cn&edition=full","pubTime":"2024-11-01 00:00","pubTimestamp":1730390428,"startTime":"0","endTime":"0","summary":"11月1日，徕博科公布财报，公告显示公司2024财年第三财季净利润为1.69亿美元，同比减少7.65%；其中营业收入为32.82亿美元，同比增加7.36%，每股基本收益为2.02美元。从资产负债表来看，徕博科总负债104.27亿美元，其中短期债务15.91亿美元，资产负债比为1.79，流动比率为1.44。机构评级：截至2024年11月1日，当前有16家机构对徕博科目标价做出预测，其中目标均价为263.69美元，其中最低目标价为231.00美元，最高目标价为293.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101000032ab8c4381&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241101000032ab8c4381&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.labcorp.com","stockEarnings":[{"period":"1week","weight":-0.0449},{"period":"1month","weight":-0.013},{"period":"3month","weight":0.0603},{"period":"6month","weight":0.0025},{"period":"1year","weight":0.0813},{"period":"ytd","weight":0.0906}],"compareEarnings":[{"period":"1week","weight":-0.0118},{"period":"1month","weight":-0.0179},{"period":"3month","weight":-0.007},{"period":"6month","weight":0.04},{"period":"1year","weight":0.1777},{"period":"ytd","weight":-0.0054}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Labcorp Holdings Inc.是特拉华州的一家公司，成立于1971年。公司是一家领先的全球生命科学公司，已在指导患者护理方面深入整合。公司通过其LabCorp诊断（LCD）和Covance药物开发（CDD）部门提供全面的临床实验室和端到端药物开发服务。LabCorp定位于研究和护理交付的融合，以实现更精确和个性化的医疗保健，将世界一流的诊断和药物开发能力结合在一起。","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.026972},{"month":2,"riseRate":0.612903,"avgChangeRate":0.024969},{"month":3,"riseRate":0.612903,"avgChangeRate":-0.006861},{"month":4,"riseRate":0.7,"avgChangeRate":0.055176},{"month":5,"riseRate":0.5,"avgChangeRate":0.008236},{"month":6,"riseRate":0.580645,"avgChangeRate":0.025464},{"month":7,"riseRate":0.483871,"avgChangeRate":0.008997},{"month":8,"riseRate":0.451613,"avgChangeRate":-0.030248},{"month":9,"riseRate":0.451613,"avgChangeRate":-0.0037},{"month":10,"riseRate":0.548387,"avgChangeRate":-0.003333},{"month":11,"riseRate":0.677419,"avgChangeRate":0.00863},{"month":12,"riseRate":0.709677,"avgChangeRate":0.014463}],"exchange":"NYSE","name":"徕博科","nameEN":"Labcorp Holdings Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供徕博科(LH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"徕博科,LH,徕博科股票,徕博科股票老虎,徕博科股票老虎国际,徕博科行情,徕博科股票行情,徕博科股价,徕博科股市,徕博科股票价格,徕博科股票交易,徕博科股票购买,徕博科股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"徕博科(LH)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供徕博科(LH)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}